OssDsign: Promising data from TOP FUSION’s top-line results - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

OssDsign: Promising data from TOP FUSION’s top-line results - Redeye

{newsItem.title}

Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further peer-reviewed publication in the intended journal. We anticipate a continuous positive share price development on the back of the news and ahead of the Q4 2023 report in mid-February. We reiterate our SEK15 base case, representing a c60% upside, which we believe should close during the year.

Länk till analysen i sin helhet: https://www.redeye.se/research/969794/ossdsign-promising-data-from-top-fusions-top-line-results?utm_source=finwire&utm_medium=RSS

Nyheter om OssDsign

Läses av andra just nu

Om aktien OssDsign

Senaste nytt